TY  - JOUR
TI  - Real-world efficacy and safety of Ledipasvir + Sofosbuvir andOmbitasvir/Paritaprevir/Ritonavir ± Dasabuvir combinationtherapies for chronic hepatitis C: A Turkish experience
AB  - Background/Aims: This study aimed to evaluate the real-life efficacy and tolerability of direct-acting antiviral treatments for patients with chronic hepatitis C (CHC) with/without cirrhosis in the Turkish population.Material and Methods: A total of 4,352 patients with CHC from 36 different institutions in Turkey were enrolled. They received ledipasvir (LDV) and sofosbuvir (SOF)±ribavirin (RBV) ombitasvir/paritaprevir/ritonavir±dasabuvir (PrOD)±RBV for 12 or 24 weeks. Sustained virologic response (SVR) rates, factors affecting SVR, safety profile, and hepatocellular cancer (HCC) occurrence were analyzed.Results: SVR12 was achieved in 92.8% of the patients (4,040/4,352) according to intention-to-treat and in 98.3% of the patients (4,040/4,108) according to per-protocol analysis. The SVR12 rates were similar between the treatment regimens (97.2%–100%) and genotypes (95.6%–100%). Patients achieving SVR showed a significant decrease in the mean serum alanine transaminase (ALT) levels (50.90±54.60 U/L to 17.00±14.50 U/L) and model for end-stage liver disease (MELD) scores (7.51±4.54 to 7.32±3.40) (p<0.05). Of the patients, 2 were diagnosed with HCC during the treatment and 14 were diagnosed with HCC 37.0±16.0 weeks post-treatment. Higher initial MELD score (odds ratio [OR]: 1.92, 95% confidence interval [CI]: 1.22–2.38; p=0.023]), higher hepatitis C virus (HCV) RNA levels (OR: 1.44, 95% CI: 1.31–2.28; p=0.038), and higher serum ALT levels (OR: 1.38, 95% CI: 1.21–1.83; p=0.042) were associated with poor SVR12. The most common adverse events were fatigue (12.6%), pruritis (7.3%), increased serum ALT (4.7%) and bilirubin (3.8%) levels, and anemia (3.1%).Conclusion: LDV/SOF or PrOD±RBV were effective and tolerable treatments for patients with CHC and with or without advanced liver disease before and after liver transplantation. Although HCV eradication improves the liver function, there is a risk of developing HCC.
AU  - Yapali, Suna
AU  - Dincer, Dinc
AU  - Akin, Mete
AU  - Kaçar, Sabite
AU  - Gokcan, Hale
AU  - Dursun, Hakan
AU  - akarsu, mesut
AU  - Danis, Nilay
AU  - DEMİRCAN, melek
AU  - Temel, Tuncer
AU  - OZAKYOL, AYSEGÜL
AU  - YILDIRIM, EMRE
AU  - Balkan, Ayhan
AU  - ÖZENİRLER, Seren
AU  - GROUP, TASL Viral Hepatitis Special Interest
AU  - NURİYEV, Kenan
AU  - akbulut, sabiye
AU  - vatansever, sezgin
AU  - Erarslan, Elife
AU  - Ucbilek, Enver
AU  - özdoğan, osman
AU  - Yaraş, Serkan
AU  - Soylu, Aliye
AU  - SEN, ILKER
AU  - ÇETİN, Hayrettin
AU  - Akdogan, Meral
AU  - Poturoglu, Sule
AU  - Kani, Haluk Tarik
AU  - Degertekin, Bulent
AU  - BALKAN, YASEMIN
AU  - ayyıldız, talat
AU  - albayrak, bulent
AU  - simsek, halis
AU  - Yalçın, Kendal
AU  - Akarca, Ulus Salih
AU  - karasu, zeki
AU  - ÖZTAŞKIN, SİNEM
AU  - uğurlu, çağrı burak
AU  - GÜNEŞ, Şevki
AU  - İNCİ, ismail
AU  - Alkim, Huseyin
AU  - DOGANAY, HAMDI LEVENT
AU  - Aladag, Murat
AU  - Uyanikoglu, Ahmet
AU  - Dilber, Feyza
AU  - Kaymakoglu, Sabahattin
AU  - HARPUTLUOĞLU, MURAT
AU  - Irak, Kader
AU  - GUREL, SELIM
AU  - Günşar, Fulya
AU  - Beşışık, Fatih
AU  - Mert, Ali
AU  - Idilman, Ramazan
AU  - Sezgin, Orhan
AU  - AKYILDIZ, Murat
AU  - Demir, Mehmet
AU  - Kefeli, Ayşe
AU  - Coban, Mehmet
AU  - ÇALISKAN KARTAL, AYSUN
AU  - GOKTURK, HUSEYIN SAVAS
AU  - Güzelbulut, Fatih
AU  - COSAR, Arif Mansur
AU  - Atalay, Roni
DO  - 10.5152/tjg.2020.20696
PY  - 2020
JO  - Turkish Journal of Gastroenterology
VL  - 31
IS  - 12
SN  - 1300-4948
SP  - 883
EP  - 893
DB  - TRDizin
UR  - http://search/yayin/detay/453250
ER  -